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Franchette W. P. J. van den Berkmortel8, Jan-Willem B. de Groot9, Geke A. P. Hospers10, Ellen Kapiteijn11, Djura Piersma12,
Roos S. van Rijn13, Karijn P. M. Suijkerbuijk14, Willeke A. M. Blokx15, Bert-Jan J. ten Tije16, Astrid A. M. van der Veldt 17,
Art Vreugdenhil18, Marye J. Boers-Sonderen19 and Alfonsus J. M. van den Eertwegh2
BACKGROUND: Anti-PD-1 antibodies and BRAF/MEK inhibitors are the two main groups of systemic therapy in the treatment of
BRAFV600-mutant advanced melanoma. Until now, data are inconclusive on which therapy to use as first-line treatment. The aim of
this study was to use propensity score matching to compare first-line anti-PD-1 monotherapy vs. BRAF/MEK inhibitors in advanced
BRAFV600-mutant melanoma patients.
METHODS: We selected patients diagnosed between 2014 and 2017 with advanced melanoma and a known BRAFV600-mutation
treated with first-line BRAF/MEK inhibitors or anti-PD-1 antibodies, registered in the Dutch Melanoma Treatment Registry. Patients
were matched based on their propensity scores using the nearest neighbour and the optimal matching method.
RESULTS: Between 2014 and 2017, a total of 330 and 254 advanced melanoma patients received BRAF/MEK inhibitors and anti-PD-
1 monotherapy as first-line systemic therapy. In the matched cohort, patients receiving anti-PD-1 antibodies as a first-line treatment
had a higher median and 2-year overall survival compared to patients treated with first-line BRAF/MEK inhibitors, 42.3 months (95%
CI: 37.3-NE) vs. 19.8 months (95% CI: 16.7–24.3) and 85.4% (95% CI: 58.1–73.6) vs. 41.7% (95% CI: 34.2–51.0).
CONCLUSIONS: Our data suggest that in the matched BRAFV600-mutant advanced melanoma patients, anti-PD-1 monotherapy is
the preferred first-line treatment in patients with relatively favourable patient and tumour characteristics.
British Journal of Cancer https://doi.org/10.1038/s41416-020-01229-1
BACKGROUND
Over the last decade, new systemic treatment options have
emerged in the treatment of metastatic melanoma. These
approved treatments can be divided into two main groups:
targeted therapy consisting of BRAF and MEK inhibitors1,2 and
immunotherapy, anti-PD-1 and anti-CTLA-4 monoclonal antibo-
dies.3–5 Their introduction has increased the overall survival of
these patients.2,6 Based on clinical consensus, treatment choice
depends on several prognostic and predictive factors such as
BRAF-mutation status, lactate dehydrogenase levels (LDH), per-
formance status and the tumour stage.
As BRAF/MEK inhibitors have a rapid onset and a high overall
response rate (ORR), they are often considered the preferred primary
treatment for patients with extensive (symptomatic) disease and a
BRAFV600-mutation. However, in such patients, the response
duration is relatively short due to acquired resistance.7 As time to
response for immunotherapy is generally longer and ORR lower,
checkpoint inhibition is usually not the preferred treatment for
BRAF-mutant patients with poor prognostic factors such as a poor
performance score or elevated LDH.8 Therefore, the perception that
checkpoint inhibition leads to more durable responses could at least
partially be explained by the fact that patients with better
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prognostic factors are being treated with immunotherapy. Although
interstudy comparison suggests that immunotherapy results in more
durable responses as compared to targeted therapy,9 these results
need to be interpreted with caution due to the potential biases
associated with this type of analysis.
Due to the confounding by indication bias, a head-to-head
comparison between both groups, based on real-world data is
difficult. Propensity score matching, a statistical method devel-
oped by Rosenbaum and Rubins,10 accounts for the unequal
distribution of confounders. A propensity score is the chance of
receiving the treatment, based on measured confounders such as
age and tumour stage.11,12 This method matches patients based
on their propensity score, creating two groups with similar
distribution of confounders.
In this study, we (1) compare OS of BRAF/MEK inhibitors and
anti-PD-1 monotherapy in BRAF-mutant advanced melanoma
patients, and (2) use propensity score matching to determine the
overall survival in the BRAF/MEK inhibitors vs. anti-PD-1 mono-
therapy groups after matching.
METHODS
Study design and population
This longitudinal observational study used data from the Dutch
Melanoma Treatment Registry (DMTR), a population-based,
prospective registry capturing all patients with unresectable
stage IIIc and IV melanoma in the Netherlands. Since the 1 July
2013, all patients with unresectable stage IIIC or stage IV
melanoma seen in one of the 14 melanoma centres have been
registered in the DMTR. Data are prospectively registered from
diagnosis until death. Patients are followed every three months
for changes in disease status, patients’ characteristics or
treatment characteristics by an independent trained data
manager. A detailed description of the DMTR setup has been
published by Jochems et al.13
All patients of 18 years and older, diagnosed between 2014 and
2017 (dataset cut-off date was 01-08-2019) with unresectable
stage IIIC and IV melanoma, with a known BRAFV600-mutation who
used anti-PD-1 monotherapy (pembrolizumab or nivolumab) or
BRAF/MEK inhibitors (dabrafenib+ trametinib or vemurafenib+
cobimetinib) as a first-line systemic therapy, were selected for
analysis. Combination therapies of encorafenib+ binimetinib and
ipilimumab+ nivolumab were not yet available during this time
period. Line of therapy was defined as the start of a new drug
class. Patients with uveal or mucosal melanoma were excluded
from this analysis.
Statistical analysis
Baseline patient- and disease characteristics of BRAFV600-mutant
patients were analysed using descriptive statistics. Categorical
variables were compared using the Chi-square test. Overall
survival (OS) was defined as time from start systemic treatment
until death from any cause with corresponding two-sided 95%
confidence intervals and was estimated using the Kaplan–Meier
method. TTNT was defined as the time until next treatment of a
new drug class or death from any cause. OS and TTNT between
subgroups was compared using log-rank tests for categorical
variables. Patients alive or lost to follow-up were right-censored at
the time of last registered contact.
In order to reduce confounding by indication, propensity score
matching was used. As a first step, a multivariable logistic
regression analysis was used to estimate propensity scores.
Covariates used for the multivariable logistic regression were
age at diagnosis (<75, ≥75), baseline ECOG-performance status
(0–1 and ≥2), baseline lactate dehydrogenase (LDH) (normal,
250–500 U/L and >500 U/L), stage at diagnosis (unresectable IIIc,
IV-M1a, M1b and IV-M1c), distant metastasis (<3 organ sites and
≥3 organ sites involved), brain metastases (none, asymptomatic,
and symptomatic) and liver metastases (yes/no) and use of
immunomodulating agents (corticosteroids, azathioprine and
interferon). Covariates were chosen based on clinical practice
and previous research identifying these prognostic risk factors.14,15
A Monte Carlo simulation study has demonstrated that his
method of selecting covariates for propensity score matching
works very well.16
A multivariable Cox proportional hazards model was used to
assess the association of prognostic factors with OS. Prognostic
factors estimated were age at diagnosis (<75, ≥75), baseline
ECOG-performance status (0–1 and ≥2), baseline lactate dehy-
drogenase (LDH; normal, 250–500 U/L and >500 U/L), distant
metastases (<3 organ sites and ≥3 organ sites involved), brain
metastases (none, asymptomatic and symptomatic) and liver
metastases (yes/no). The proportional hazards assumption was
tested with the scaled Schoenfeld residuals. None of the
covariates violated the proportional hazards assumption.
For matching purposes, 1:1 nearest neighbour matching with a
calliper set of 0.001 was used for propensity score matching. To
assess the quality of matching, standardised mean differences for
all covariates were calculated. Standardised mean differences of
<0.1 were assumed to be negligible. After matching, a univariable
Cox proportional hazards model with a robust variance estimator
to account for the matched nature of the sample was used to
estimate the relative change in hazard of survival.17,18 To address
potential biases due to incomplete matching, we compared our
results to a second matched sample set using optimal matching.
Optimal matching forms matched pairs to minimise the average
within-pair difference in propensity scores.19 We used both
matching techniques in order to observe the influence of well-
balanced prognostic factors across both groups in the nearest
neighbour-matched group on OS and TTNT compared to the
optimal matching method. Due to the matched nature, the use of
a log-rank test comparing the survival curves will likely result in
type I error rates that are artificially low,20 stratified log-rank tests
were used to compare the survival curves of the matched
samples.18 Statistical software used was R (version 3.5.2; packages
car, tidyverse, survival and matchit).
RESULTS
Patient characteristics
Between 1-1-2014 and 31-12-2017, a total of 330 and 254 BRAF-
mutant patients with unresectable stage IIIc or IV melanoma
received BRAF/MEK inhibitors or anti-PD-1 monotherapy, respec-
tively, as first-line systemic therapy (Fig. 1). Overall, patients
receiving BRAF/MEK inhibitors as a first-line systemic treatment
had a higher ECOG-performance status (≥2: 23.0% vs. 8.7%),
elevated LDH levels, (50.3% vs 22.4%), IV-M1c disease (87.6% vs.
67.3%), brain metastases (41.8% vs. 18.5%), liver metastases
(33.9% vs. 21.3%) and metastases in more organ sites (≥3 organ
sites: 59.4% vs. 42.5%) (Table 1). There was no significant
difference in age and gender between patients receiving first-
line treatment with BRAF/MEK inhibitors and anti-PD-1 ligands.
Median follow-up time, calculated with a reverse Kaplan–Meier
was 28.3 months for the total population. Subsequent therapies
are shown in Supplement 1 and subsequent therapies of pro-
gressive patients are shown in Supplement 2. Overall, progressive
patients that received first-line BRAF/MEK inhibitors receive less
second and third-line therapy compared to patients receiving
first-line anti-PD-1, 61.3% vs. 94.2% and 6.5% vs.43.4%.
Predictors of receiving first-line BRAF/MEK inhibitors
To determine which factors were associated with receiving first-
line BRAF/MEK inhibitors, a multivariable logistic regression was
performed (Table 2). The results show that an ECOG-performance
status of ≥2 (OR: 1.93, 95% CI: 1.11–3.44), elevated LDH (OR: 2.84,
95% CI: 1.86–4.38) and symptomatic brain metastases (OR: 3.84,
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95% CI: 2.56–7.12) were all associated with higher odds of
receiving first-line BRAF/MEK inhibitors. With unresectable stage
IIIc as a reference, substage IV-M1b had lower odds of receiving
first-line BRAF/MEK inhibitors (OR: 0.29, 95% CI: 0.11–0.74). Age
≥75 years, female gender, ≥3 organ sites, asymptomatic brain
metastases and liver metastases were not significantly associated
with receiving first-line BRAF/MEK inhibitors (p > 0.05).
Predictors of OS
In the multivariable Cox-regression on OS analysis age of ≥75 years
(HR: 1.53, 95% CI: 1.10–2.13), ECOG-performance status ≥2 (HR:
2.30, 95% CI: 1.76–3.01), LDH > 500 U/L (HR: 3.38, 95% CI: 2.34–4.89)
and symptomatic brain metastases (HR: 1.87, 95% CI: 1.44–2.43)
were associated with a higher hazard of death. Female gender,
asymptomatic brain metastases, liver metastases and ≥3 organ
sites were not associated with a higher hazard of death (Table 3).
Propensity score matching
After 1:1 nearest neighbour propensity score matching, 310
patients were included in the final analysis: 155 patients who
received first-line BRAF/MEK inhibitors (50%) and 155 patients
who received first-line anti-PD-1 (50%). Groups did not differ with
regards to age (median age: 62 vs. 62 years), gender (47.7% vs
47.7% female), ECOG-performance status ≥2 (7.1% vs. 7.1),
elevated LDH > 250 U/L (30.3% vs. 30.3%), stage IV-M1c (77.4%
vs. 77.4%), organ sites ≥3 (45.8% vs. 45.2%), brain metastases
(22.6% vs. 22.6%), liver metastases (21.9% vs1 21.9%) and
immunomodulating agents (13.5% vs. 13.5%). These results
confirm satisfactory propensity score matching.
In total, 274 patients were not matched: 175 patients who
received first-line BRAF-MEK and 99 patients receiving anti-PD-1 as
a first-line treatment (Supplement 3). Overall, nonmatched
patients who received BRAF/MEK inhibitors as first-line systemic
Total number of patients in
the DMTR diagnosed
between 2014 and 2017
(N = 3462)
Total number of patients
without a V600-BRAF
mutation (N = 1602)
Total number not treated
with anti-PD-1 monotherapy
or BRAF-MEK inhibitors as
first-line systemic therapy
(N = 847)
Total number of uveal






Patients with a V600 BRAF-
mutation (N = 1549)
Patients treated with anti-
PD-1monotherapy or BRAF-
MEK inhibitors as first-line
systemic therapy (N = 702)
Patients treated with anti-
PD-1monotherapy as first-
line therapy (N = 254)
Patients treated with BRAF-
MEK inhibitors as first-line
therapy (N = 330)
No missing values in any of
the matching variables
(N = 584)
Fig. 1 Flow chart. Flow chart of the study population.
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therapy had poorer ECOG-performance status (ECOG-performance
status ≥2 37.1% vs. 11.1%) and more often had elevated LDH
levels (68.0% vs. 10.1%), stage IV-M1c (96.6% vs. 51.5%) more ≥3
organ sites affected (73.1% vs. 37.4%), brain metastases (58.8% vs.
12.1%), liver metastases (44.6% vs. 20.2%) and used immunomo-
dulating agents (38.3% vs. 9.1%) compared to the unmatched
patients who received anti-PD-1 monotherapy.
Clinical outcomes
In the cohort before matching, patients treated with BRAF/MEK
inhibitors as first-line systemic treatment were more likely to
die compared to patients treated with anti-PD-1 monotherapy
(p < 0.001, log-rank test). Kaplan–Meier estimates are shown
in Fig. 2. Median overall survival was 11.0 months (95%
CI: 9.9–13.7) in patients receiving first-line BRAF/MEK inhibitors
vs. 42.3 months (95% CI: 34.8-NE) in patients receiving anti-PD-1
ligands as first-line therapy. Median TTNT was 7.0 months (95%
CI: 6.2–8.7) in patients receiving first-line BRAF/MEK inhibitors vs.
18.9 months (95%CI: 11.0–24.4) in patients receiving anti-PD-1
ligands as first-line therapy. Six and twelve-month OS were also
lower for first-line BRAF/MEK inhibitors compared to anti-PD-1
monotherapy, 75.9% (95% CI: 71.4–80.7) and 47.7% (95%
CI: 42.6–53.4) vs. 91.3% (95% CI: 87.9–94.8) and 81.7% (95%
CI: 77.0–86.6) (Table 4).
Nearest neighbour propensity matching. In the nearest
neighbour-matched cohort (N= 310), the overall survival of first-
line BRAF/MEK inhibitors was significantly lower compared to anti-
PD-1 (stratified log-rank p < 0.001). This matched cohort only
included patients treated with anti-PD-1 and BRAF/MEK inhibitors
in which the propensity score of both patients was within the pre-
set calliper. Median OS of first-line BRAF/MEK inhibitors was lower
compared to the anti-PD-1 cohort, 19.8 months (95% CI: 16.7–24.3)
vs. 42.3 (95% CI 37.3-NE). Median TTNT of first-line BRAF/MEK
Table 1. Baseline characteristics.
Original sample Nearest neighbour-matched sample
BRAF-MEK Anti-PD-1 p value BRAF-MEK Anti-PD-1 SMD
Baseline variable (N= 330) (N= 254) (N= 155) (N= 155)
Age, median (range) 59 (19–91) 62 (22–87) 0.177 62 (19–91) 62 (25–87) 0.027
Gender
Male 178 (53.9) 145 (57.1) 0.500 81 (52.3) 81 (52.3) <0.001
Female 152 (46.1) 109 (42.9) 74 (47.7) 74 (47.7)
ECOG-performance status
0–1 254 (77.0) 232 (91.3) <0.001 144 (92.9) 144 (92.9) <0.001
≥2 76 (23.0) 22 (8.7) 11 (7.1) 11 (7.1)
LDH
Not determined/normal 164 (49.7) 197 (77.6) <0.001 108 (69.7) 108 (69.7) <0.001
250–500 U/L 108 (32.7) 55 (21.7) 45 (29.0) 45 (29.0)
>500 U/L 58 (17.6) 2 (0.8) 2 (1.3) 2 (1.3)
Stage (7th edition AJCC)
Unresectable IIIc 15 (4.5) 14 (5.5) <0.001 10 (6.5) 10 (6.5) <0.001
IV-M1a 13 (3.9) 29 (11.4) 13 (8.4) 13 (8.4)
IV-M1b 13 (3.9) 40 (15.7) 12 (7.7) 12 (7.7)
IV-M1c 289 (87.6) 171 (67.3) 120 (77.4) 120 (77.4)
Brain metastases
No 192 (58.2) 207 (81.5) <0.001 120 (77.4) 120 (77.4) <0.001
Yes. asymptomatic 42 (12.7) 24 (9.4) 15 (9.7) 15 (9.7)
Yes. symptomatic 96 (29.1) 23 (9.1) <0.001 20 (12.9) 20 (12.9)
Liver metastases
No 218 (66.1) 200 (78.7) 121 (78.1) 121 (78.1) <0.001
Yes 112 (33.9) 54 (21.3) 34 (21.9) 34 (21.9)
Organ sites
0–2 134 (40.6) 146 (57.5) 0.001 86 (55.5) 83 (53.5) <0.001
≥3 196 (59.4) 108 (42.5) 69 (44.5) 72 (46.5)
Immunomodulating agents
No 242 (73.3) 224 (88.2) <0.001 134 (86.5) 134 (86.5) <0.001
Yes 88 (26.7) 30 (11.8) 21 (13.5) 21 (13.5) <0.001
BRAFV600-mutation
V600E 274 (83.0) 212 (83.5) 0.833 130 (83.9) 132 (85.2) 0.073
V600K 44 (13.3) 35 (13.8) 19 (12.3) 19 (12.3)
V600R/D/E2 12 (3.6) 7 (2.8) 6 (3.9) 4 (2.6)
Comparison of baseline characteristics of patients receiving BRAF/MEK inhibitors or anti-PD-1 as a first-line treatment in the original sample and the matched
sample.
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inhibitors was not significantly lower compared to the anti-PD-1
cohort, 10.1 months (95% CI: 7.7–15.0) vs. 14.6 (95% CI 10.1–27.7).
Six-, 12-and 24-month OS was also lower for BRAF/MEK inhibitors
compared to anti-PD-1 monotherapy, 92.9% (95% CI: 89.9–97.0),
83.0% (95% CI: 77.3–89.2) and 65.4% (58.1–73.6) vs. 84.3% (95% CI:
78.7–90.3), 65.3% (95% CI: (58.2–73.3) and 41.7% (95% CI:
34.2–51.0) (Table 4). Kaplan–Meier estimates of the nearest
neighbour-matched cohort are shown in Fig. 3. The estimated
HR with a robust variance estimator was 0.50 (95% CI: 0.36–0.70)
Thus, treatment with first-line anti-PD-1 ligands reduced the
hazard of death by 50% in this matched sample. Overall survival of
the nonmatched patients receiving BRAF/MEK inhibitors was
significantly lower compared to anti-PD-1 (log-rank p < 0.001)
(Supplement 4).
Optimal matching. In the optimal matched cohort (N= 508),
overall survival was significantly lower for BRAF/MEK inhibitors
compared to anti-PD-1 monotherapy (stratified log-rank p <
0.001). This matched cohort included all patients treated with
first-line anti-PD-1 matched with the most alike set of patients
treated with first-line BRAF/MEK inhibitors. Median OS of first-line
BRAF/MEK inhibitors was lower compared to anti-PD-1 mono-
therapy, 15.6 months (95% CI: 12.4–19.1). vs. 42.3 months (95% CI:
34.4-NE). Median TTNT of first-line BRAF/MEK inhibitors was lower
compared to anti-PD-1 monotherapy, 7.6 months (95% CI: 6.1–9.9).
vs. 18.9 months (95% CI: 11.0–24.4). Six-, 12-and 24-month OS was
also lower for BRAF/MEK inhibitors compared to anti-PD-1
monotherapy, 83.7% (95% CI: 79.3–88.4), 57.1% (95% CI:
51.3–63.6) and 34.4 (95% CI: 28.7–41.3) vs. 91.3% (95% CI:
87.9–94.8), 81.7% (95% CI: 77.0–86.6) and 64.0 (95% CI:
58.2–70.4) (Table 4). Kaplan–Meier estimates of the optimal
matched cohort are shown in Fig. 4. The estimated HR with a
robust variance estimator was 0.43 (95% CI: 0.34–0.56). Thus,
treatment with first-line anti-PD-1 reduced the hazard of death by
57% in the optimal matched sample.
DISCUSSION
This report, based on real-world population-based data, describes
the overall survival of BRAFV600-mutant advanced melanoma
patients after using first-line treatment with BRAF-MEK inhibitors
or anti-PD-1 monotherapy. In total 310 patients were matched,
resulting in 155 matched pairs. In the matched cohort, patients
treated with anti-PD-1 monotherapy as a first-line treatment
showed a higher 2-year survival compared to patients treated with
first-line BRAF-MEK. Median OS in the anti-PD-1 monotherapy
cohort was 42.3 months while the median OS was 19.8 months in
patients receiving BRAF/MEK inhibitors as first-line treatment.
In the nearest neighbour-matched cohort, patients treated with
anti-PD-1 as a first-line treatment have higher OS compared to
patients treated with BRAF/MEK inhibitors as a first-line treatment.
There were also patients who could not be matched. Overall, we
matched patients with relatively good prognosis factors who
Table 2. Multivariable logistic regression.
Variables OR 95% CI p value
(Intercept) 0.84 (0.40–1.82) 0.659
Age (categories)
<75 years Ref
≥75 years 1.54 (0.86–2.78) 0.149
Gender
Male Ref
Female 1.34 (0.92–1.95) 0.132
ECOG-performance status
0–1 Ref
≥2 1.59 (0.89–2.89) 0.123
LDH
Not determined/normal Ref
250–500 U/L 2.03 (1.86–4.38) 0.002
>500 U/L 30.73 (8.77–195.30) <0.001
Stage (7th edition AJCC)
Unresectable IIIc Ref
IV-M1a 0.47 (0.17–1.27) 0.140
IV-M1b 0.33 (0.12–0.88) 0.029
IV-M1c 0.58 (0.25–1.34) 0.201
Organ sites
0–2 Ref
≥3 1.52 (0.98–2.35) 0.063
Brain metastases
No Ref
Yes, asymptomatic 1.40 (0.76–2.60) 0.279
Yes, symptomatic 3.97 (2.22–7.35) <0.001
Liver metastases
No Ref
Yes 0.89 (0.54–1.45) 0.629
Immunomodulating agents
No Ref
Yes 1.41 (0.81–2.47) 0.222
Multivariable logistic regression of receiving first-line BRAF-MEK inhibitor
treatment.
LDH lactate dehydrogenase, OR odds ratio, CI confidence interval.
Table 3. Multivariable Cox-regression analysis of OS.
N HR 95% CI p value
Age
<75 years 520 1
≥75 years 64 1.53 (1.10–2.13) 0.012
Gender
Female 323 1
Male 261 0.94 (0.75–1.17) 0.585
ECOG-performance status
0–1 486 1
≥2 98 2.30 (1.76–3.01) <0.001
LDH
Normal 361 1
250–500 U/L 163 1.28 (0.99–1.65) 0.065
>500 U/L 60 3.38 (2.34–4.89) <0.001
Brain metastases
No 399 1
Yes, asymptomatic 66 1.36 (0.97–1.92) 0.076
Yes, symptomatic 119 1.87 (1.44–2.43) <0.001
Liver metastases
No 418 1
Yes 166 1.18 (0.9–1.55) 0.241
Number of organ sites
0–2 289 1
≥3 295 1.25 (0.96–1.62) 0.096
LDH lactate dehydrogenase, HR hazard ratio, CI confidence interval.
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received BRAF/MEK inhibitors with patients with relatively poor
prognosis factors who received anti-PD-1 monotherapy as first-line
systemic therapy. The unmatched patients consisted of patients
with poor prognostic factors who received BRAF/MEK inhibitors as
first-line therapy and the patients with good prognostic factors
who received anti-PD-1 as first-line systemic therapy. In the optimal
matching method, we matched all patients receiving first-line anti-
PD-1, resulting in lower OS for BRAF/MEK inhibitors as sicker
patients were matched, which could, in turn, lead to residual
confounding.18 Consequently, we cannot compare the efficacy of
BRAF/MEK inhibitors or anti-PD-1 in the unmatched group. In
BRAF-mutant patients with a very poor prognosis, BRAF-MEK
inhibitors might be the preferred choice of first-line treatment as
this treatment results in quick antitumour response.21
This study suggests that in the matched cohort, consisting
of patients with relative favourable patient and tumour character-
istics, anti-PD-1 monotherapy is the first-line treatment option of
choice. However, the results need to be confirmed in randomised
clinical trials to assess optimal front-line-and sequence therapy.
Currently, several clinical trials are investigating the optimal front-
line treatment of immunotherapy and targeted therapy. The
COWBOY study evaluates a planned sequence vemurafenib and
cobimetinib, followed by ipilimumab and nivolumab vs. ipilimu-
mab and nivolumab (NCT02968303).22 The DREAMseq study
(NCT02224781) evaluates a sequence of dabrafenib and trameti-
nib until progression, followed by ipilimumab and nivolumab or
ipilimumab and nivolumab until progression followed by dabra-
fenib and trametinib. The SECOMBIT (NCT02631447) evaluates the
sequence of encorafenib plus binimetinib followed by ipilimumab
plus nivolumab or the opposite sequence or encorafenib plus
binimetinib for 8 weeks followed by ipilimumab plus nivolumab
until progression followed by encorafenib plus binimetinib.23,24
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Fig. 2 Kaplan–Meier estimate of OS and TTNT of first-line BRAF/MEK inhibitors vs. anti-PD-1 monotherapy. Kaplan–Meier estimate of OS
(left) and TTNT (right) of first-line BRAF/MEK inhibitors vs. anti-PD-1 monotherapy. Confidence interval is displayed by the shadow of both
curves.



























































































TTNT and OS estimates shown as survival rates at 6,12 and 24 months and median overall survival stratified for first-line therapy (BRAF/MEK inhibitors vs. anti-
PD-1 monotherapy).
NE non estimable.
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In Phase 3 RCT’s, 1-year survival was 74.1% for pembrolizumab
and 72.9% for nivolumab.4,25 Comparing the results of this study
with the randomised clinical trials of both anti-PD-1 ligands, we find
a higher 1-year survival (81.7%, 95% CI: 77.0–86.6). This is
remarkable because we would expect 1-year survival of patients
treated in clinical practice to be similar or worse due to
unfavourable patient and tumour characteristics. However, in the
CHECKMATE-066 study, only BRAF wild-type patients were included
and the KEYNOTE-006 included only 35% of BRAF-mutant patients.
These patients lack treatment options with BRAF/MEK inhibitors,
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Fig. 3 Kaplan–Meier estimate OS and TTNT of the nearest neighbour-matched sample. Kaplan–Meier estimates of OS (left) and TTNT (right)
for the nearest neighbour-matched cohort. Confidence interval is displayed by the shadow of both curves.
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Fig. 4 Kaplan–Meier estimate of the optimal matched sample. Kaplan–Meier estimates of OS (left) and TTNT (right) for the optimal matched
cohort. Confidence interval is displayed by the shadow of both curves.
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which may result in fewer treatment options available after
progression on anti-PD-1 treatment. On the other hand, in our
matched anti-PD-1 cohort, 7.1% of patients had a baseline ECOG-
performance status of ≥2. These patients have been excluded from
the previously mentioned RCT’s and as a result, we would expect
that the clinical outcomes of this study would be worse compared
to RCT’s. Compared to Phase 3 RCT’s of BRAF/MEK inhibitors, one
year survival was 71.2% for dabrafenib and trametinib and 74.5%
for vemurafenib and cobimetinib.2,26 Compared to the 1-year
survival of this study, we find a lower 1-year survival of 65.3% (95%
CI: 58.2–73.3). Differences in survival could be related to a higher
age (62 vs. 55), inclusion of ECOG ≥ 2 (7.1%), more patients with IV-
M1c disease (77% vs. 62–63%) and inclusion of patients with brain
metastases (22.6%) in our matched sample.
Another real-world study investigating the outcomes of first-line
immunotherapy and targeted therapy was performed by Luke
et al.27 Opposed to our current study, they find a lack of survival
benefit for patients receiving first-line immunotherapy, despite a
favourable imbalance of prognostic factors. These differences could
be explained by the percentage of M1c patients (77.4%) in our study
vs. 59.7% and 51.6% in the study by Luke et al. A direct comparison
between both studies is hard due to differences in patient and
tumour characteristics, study design and geographic location.
There are limitations to this study. First, this study did not
include patients who received ipilimumab monotherapy or
ipilimumab combined with nivolumab. Ipilimumab monotherapy
is no longer given as first-line treatment since anti-PD-1 has
proven superior efficacy.28 However, combination therapy of
ipilimumab and nivolumab has proven to be effective in
metastatic melanoma patients in the CHECKMATE-067 trial.29 We
did not have enough patients who received combination therapy
of ipilimumab and nivolumab to make a reliable analysis of this
group. Second, the observational nature of the DMTR may have
introduced bias. However, since the start of this registry,
independent data managers have been trained annually and data
are checked and confirmed by treating physicians. The online
registration platform warns data managers of inconsistent or
missing values in the registry. Previous studies have shown the
quality and validity of the Dutch population-based registries.30 We
therefore argue that the data used in this study is of high quality.
The third limitation is that we could not assess how subsequent
therapies impact the outcome. By studying patients receiving
second-line treatment, we would introduce a selection bias. Only
patients fit enough would be able to receive second-line
treatment. Studying the impact of subsequent therapies on
outcomes would require a randomised controlled trial with
several predefined arms. In the real-world, choice of type of
subsequent therapy depends on patient and tumour character-
istics as well as preference of the oncologist.
Based on the matched cohort, our data suggest that in
BRAFV600-mutant cutaneous metastatic melanoma patients, anti-
PD-1 monotherapy should be the preferred treatment if a quick
antitumour response, for example for symptom relief, is not the
primary aim of treatment. Additional results from RCTs are
necessary to confirm these results to determine optimal front-
line and sequential therapy for BRAF-mutant cutaneous metastatic
melanoma patients.
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